Indeed, the use of COX-2 inhibitors combined with conventional chemotherapy improved anti-tumor activity and patient tolerability (22, 23) and demonstrated antiangiogenic (24) and pro-apoptotic (25, 26) functions. This evidence concerns the gene PTGS2 and neoplasm.